```json
{
"ranked_hypotheses": [
{
"rank": 1,
"id": "H6",
"title": "HSP90B1 ERES Formation for Aggregate Secretion",
"theorist_confidence": 0.44,
"skeptic_confidence": 0.24,
"expert_confidence": 0.24,
"composite_score": 0.36,
"scores": {
"mechanistic_plausibility": 0.35,
"evidence_strength": 0.35,
"novelty": 0.40,
"feasibility": 0.25,
"therapeutic_potential": 0.40,
"druggability": 0.40,
"safety_profile": 0.25,
"competitive_landscape": 0.35,
"data_availability": 0.30,
"reproducibility": 0.30
},
"evidence_for": [
{"claim": "HSP90B1/GRP94 is an ER chaperone essential for unconventional secretion under proteostatic stress", "pmid": "29987195"},
{"claim": "TFG regulates ERES organization and unconventional protein trafficking", "pmid": "23091053"},
{"claim": "ER stress is activated in ALS motor neurons", "pmid": "28704975"},
{"claim": "HSP90B1 is a tractable drug target with existing inhibitors (NVP-HSP990, PU-H71)", "pmid": "26124442"},
{"claim": "PIKFYVE inhibition activates compensatory ER stress responses", "pmid": "36754049"}
],
"evidence_against": [
{"claim": "ERES formation is definitionally COPII-dependent; 'COPII-independent ERES' has no biochemical mechanism", "pmid": "23091053"},
{"claim": "HSP90B1 is an ER lumen chaperone with no demonstrated membrane-nucleating function", "pmid": "29987195"},
{"claim": "TFG mutations cause neuropathy by impairing ER export (HSP), supporting TFG as export-promoting, not enhancing secretion", "pmid": "23091053"},
{"claim": "ER stress typically activates ERAD, not unconventional secretion", "pmid": "28704975"},
{"claim": "HSP90 inhibitors have narrow therapeutic windows and cause liver toxicity", "pmid": "26124442"}
],
"key_gaps": [
"No mechanism exists for COPII-independent ERES formation",
"HSP90B1 lumenal location incompatible with membrane organization",
"TFG biology contradicts enhanced ERES model"
],
"required_experiments": [
"SEC16A and LC3B colocalization during PIKFYVE inhibition",
"HSP90B1 knockout blocks therapeutic benefit (falsification test)",
"COPII-independent ER export reconstitution assay"
],
"red_flags": ["COPII-independent mechanism lacks biochemical validation"]
},
{
"rank": 2,
"id": "H2",
"title": "RAB27A/ALIX Lysosomal Exocytosis",
"theorist_confidence": 0.48,
"skeptic_confidence": 0.28,
"expert_confidence": 0.28,
"composite_score": 0.31,
"scores": {
"mechanistic_plausibility": 0.25,
"evidence_strength": 0.30,
"novelty": 0.45,
"feasibility": 0.20,
"therapeutic_potential": 0.35,
"druggability": 0.35,
"safety_profile": 0.15,
"competitive_landscape": 0.25,
"data_availability": 0.25,
"reproducibility": 0.25
},
"evidence_for": [
{"claim": "ALIX interactions with ubiquitinated cargo are well-characterized in endosomal sorting", "pmid": "16903783"},
{"claim": "RAB27A specifically controls lysosomal exocytosis in specialized secretory cells", "pmid": "15102840"},
{"claim": "Protein aggregates in ALS are ubiquitinated and accumulate on late endosomes", "pmid": "32873930"},
{"claim": "ALIX is a druggable target via Bro1 domain protein-protein interaction modulators", "pmid": "16903783"}
],
"evidence_against": [
{"claim": "PIKFYVE inhibition blocks autophagosome-lysosome fusion, making simultaneous lysosome exocytosis paradoxical", "pmid": "22990836"},
{"claim": "ALIX is recruited via ESCRT-III interactions, not PI(3,5)P2", "pmid": "16903783"},
{"claim": "ALIX knockdown causes tauopathy phenotypes, exacerbating aggregate accumulation", "pmid": "29189420"},
{"claim": "RAB27A is cell-type restricted (melanosomes, lytic granules) and dispensable for lysosomal exocytosis in most cells", "pmid": "22573891"},
{"claim": "Late endosomal ubiquitinated aggregates represent defective sorting, not functional clearance", "pmid": "32873930"}
],
"key_gaps": [
"Mechanistic paradox: fusion-defective lysosomes cannot simultaneously exocytose",
"No PI(3,5)P2-RAB27A regulatory link exists",
"RAB27A cell-type restriction excludes motor neurons"
],
"required_experiments": [
"TIRF microscopy for real-time lysosome-plasma membrane fusion events",
"RAB27A CRISPR knockout in motor neurons",
"Subcellular fractionation to determine aggregate localization"
],
"alternative_interpretation": "Aggregates may load onto exosomes (MVBs fuse with PM) rather than direct lysosome exocytosis—late endosomes/MVBs may retain fusion competency while autophagosomes do not",
"red_flags": ["Fundamental mechanistic paradox unresolved", "ALIX loss-of-function causes neurodegeneration"]
},
{
"rank": 3,
"id": "H4",
"title": "YKT6 SNARE Fusion for Aggregate Exocytosis",
"theorist_confidence": 0.45,
"skeptic_confidence": 0.25,
"expert_confidence": 0.25,
"composite_score": 0.29,
"scores": {
"mechanistic_plausibility": 0.30,
"evidence_strength": 0.30,
"novelty": 0.50,
"feasibility": 0.20,
"therapeutic_potential": 0.35,
"druggability": 0.30,
"safety_profile": 0.25,
"competitive_landscape": 0.20,
"data_availability": 0.25,
"reproducibility": 0.25
},
"evidence_for": [
{"claim": "YKT6 is essential for unconventional protein secretion of leaderless proteins", "pmid": "29107332"},
{"claim": "SNAP23/STX4 are plasma membrane SNAREs functioning in regulated exocytosis", "pmid": "11839689"},
{"claim": "PIKFYVE inhibition alters membrane lipid composition affecting SNARE dynamics", "pmid": "29273643"},
{"claim": "Secretory autophagy (autophagosome-PM fusion) bypasses classical secretion", "pmid": "25468908"}
],
"evidence_against": [
{"claim": "YKT6 canonically forms SNARE complexes with SNAP29 and STX17, not STX4", "pmid": "29107332"},
{"claim": "Proposed YKT6-SNAP23-STX4 complex is not a known biological combination", "pmid": "29107332"},
{"claim": "YKT6-mediated unconventional secretion handles soluble monomers, not aggregates", "pmid": "29107332"},
{"claim": "PIKFYVE inhibition causes vacuolation impairing general secretion", "pmid": "22990836"},
{"claim": "Plasma membrane-lysosome hybrid organelles are not well-characterized", "pmid": "29107332"}
],
"key_gaps": [
"Non-standard SNARE complex lacks biochemical validation",
"PI(3,5)P2 depletion-YKT6 relocalization entirely speculative",
"Organelle identity problem for hybrid compartments"
],
"required_experiments": [
"YKT6 CRISPR knockout blocks aggregate clearance (falsification)",
"Mass spectrometry of conditioned media for SNARE complexes",
"Biochemical rescue with YKT6 variants (palmitoylation mutant, PM-targeted)"
],
"red_flags": ["Non-standard SNARE complex proposed", "Aggregates cannot be packaged into conventional vesicles"]
},
{
"rank": 4,
"id": "H1",
"title": "TMED10 CUPS Pathway for Aggregate Secretion",
"theorist_confidence": 0.52,
"skeptic_confidence": 0.31,
"expert_confidence": 0.31,
"composite_score": 0.28,
"scores": {
"mechanistic_plausibility": 0.20,
"evidence_strength": 0.25,
"novelty": 0.40,
"feasibility": 0.15,
"therapeutic_potential": 0.40,
"druggability": 0.15,
"safety_profile": 0.20,
"competitive_landscape": 0.20,
"data_availability": 0.25,
"reproducibility": 0.20
},
"evidence_for": [
{"claim": "TMED10 channel identified as central component of CUPS pathway under proteostatic stress", "pmid": "31722219"},
{"claim": "TDP-43 and FUS are known substrates of unconventional secretion mechanisms", "pmid": "29395064"},
{"claim": "ALS-linked proteins enter unconventional secretion under stress", "pmid": "29395064"}
],
"evidence_against": [
{"claim": "TMED10 channel (~1nm pore) cannot translocate aggregated insoluble proteins", "pmid": "31722219"},
{"claim": "PI(3,5)P2-TMED10 link is entirely inferred with no demonstrated lipid-protein interaction", "pmid": "31722219"},
{"claim": "CUPS pathway characterized in HeLa cells, not validated in motor neurons", "pmid": "31722219"},
{"claim": "TMED10 mutations cause congenital disorders of glycosylation, impairing secretion", "pmid": "29395064"},
{"claim": "UPR activated by PIKFYVE inhibition would reduce TMED10 flux, not increase it", "pmid": "28704975"}
],
"key_gaps": [
"Fundamental substrate mismatch: CUPS handles soluble proteins, not aggregates",
"No PI(3,5)P2 regulatory domain identified in TMED10",
"Motor neuron validation absent"
],
"required_experiments": [
"In vitro TMED10 reconstitution with aggregated TDP-43/FUS",
"TMED10 knockout blocks therapeutic benefit",
"pHluorin-tagged aggregate secretion assay"
],
"red_flags": ["Substrate mismatch is fatal to hypothesis", "CUPS is for soluble leaderless proteins"]
},
{
"rank": 5,
"id": "H7",
"title": "Annexin A2/S100A10 Extracellular Degradation",
"theorist_confidence": 0.40,
"skeptic_confidence": 0.21,
"expert_confidence": 0.21,
"composite_score": 0.26,
"scores": {
"mechanistic_plausibility": 0.20,
"evidence_strength": 0.30,
"novelty": 0.30,
"feasibility": 0.20,
"therapeutic_potential": 0.35,
"druggability": 0.35,
"safety_profile": 0.30,
"competitive_landscape": 0.25,
"data_availability": 0.25,
"reproducibility": 0.25
},
"evidence_for": [
{"claim": "Annexin A2/S100A10 complex mediates extracellular matrix remodeling and protein clearance", "pmid": "24043799"},
{"claim": "Annexin A2 is expressed in motor neurons and regulates membrane-cytoskeleton dynamics", "pmid": "11891219"},
{"claim": "Extracellular proteases including plasmin degrade aggregated proteins", "pmid": "16737959"}
],
"evidence_against": [
{"claim": "This is NOT an exocytosis mechanism—represents downstream extracellular proteolysis", "pmid": "24043799"},
{"claim": "Annexin A2 lacks signal peptide and requires prior secretion via unconventional pathway", "pmid": "24043799"},
{"claim": "Annexin A2 knockout mice are viable with minimal proteostasis phenotypes", "pmid": "24043799"},
{"claim": "Extracellular proteolysis requires prior aggregate release—does not explain exocytosis"}
],
"key_gaps": [
"Mechanism is not exocytosis—incorrectly categorized in GAP",
"Requires prior exocytosis mechanism to be primary",
"Annexin A2 itself must be secreted"
],
"required_experiments": [
"ANXA2 knockout blocks extracellular aggregate degradation",
"Annexin A2 secretion status during PIKFYVE inhibition",
"Extracellular aggregate decoration with Annexin A2"
],
"red_flags": ["Not an exocytosis hypothesis—misclassified in GAP", "Downstream mechanism only"]
},
{
"rank": 6,
"id": "H5",
"title": "Microglial STX11 Granule Exocytosis",
"theorist_confidence": 0.38,
"skeptic_confidence": 0.22,
"expert_confidence": 0.22,
"composite_score": 0.23,
"scores": {
"mechanistic_plausibility": 0.15,
"evidence_strength": 0.20,
"novelty": 0.35,
"feasibility": 0.10,
"therapeutic_potential": 0.15,
"druggability": 0.30,
"safety_profile": 0.15,
"competitive_landscape": 0.30,
"data_availability": 0.20,
"reproducibility": 0.20
},
"evidence_for": [
{"claim": "STX11 controls granule exocytosis in cytotoxic lymphocytes", "pmid": "16177804"},
{"claim": "Microglia actively phagocytose and clear debris in ALS models", "pmid": "32873930"},
{"claim": "Motor neuron debris containing TDP-43 aggregates is cleared by non-cell-autonomous mechanisms", "pmid": "28753427"}
],
"evidence_against": [
{"claim": "Granule exocytosis releases granzymes for cell killing—they function intracellularly, not extracellularly", "pmid": "16177804"},
{"claim": "STX11 mutations cause hemophagocytic lymphohistiocytosis, not aggregate clearance", "pmid": "16177804"},
{"claim": "STX11 in microglia is associated with phagosome maturation, not granule exocytosis", "pmid": "24501467"},
{"claim": "Purinergic receptor-mediated phagocytosis (P2RX7, P2Y12) is the established microglial debris clearance mechanism", "pmid": "28753427"},
{"claim": "TREM2 variants are major ALS/FTD risk factors—microglial phagocytosis is TREM2-dependent", "pmid": "27974619"}
],
"key_gaps": [
"Fundamental mechanistic error: granule exocytosis cannot degrade extracellular aggregates",
"STX11 localization in microglia is endosomal/phagolysosomal, not granule",
"More validated microglial mechanisms exist (TREM2, P2RX7)"
],
"required_experiments": [
"Microglia-specific PIKFYVE deletion is sufficient for benefit",
"Test P2RX7 and TREM2 pathways instead of STX11",
"Adoptive transfer of PIKFYVE-inhibited microglia"
],
"red_flags": ["Mechanism cannot perform proposed function", "Wrong microglial pathway"]
},
{
"rank": 7,
"id": "H3",
"title": "CHCHD10/Mitochondrial-Derived Vesicle Exocytosis",
"theorist_confidence": 0.42,
"skeptic_confidence": 0.19,
"expert_confidence": 0.19,
"composite_score": 0.20,
"scores": {
"mechanistic_plausibility": 0.15,
"evidence_strength": 0.20,
"novelty": 0.40,
"feasibility": 0.10,
"therapeutic_potential": 0.15,
"druggability": 0.05,
"safety_profile": 0.15,
"competitive_landscape": 0.10,
"data_availability": 0.20,
"reproducibility": 0.15
},
"evidence_for": [
{"claim": "CHCHD10 mutations cause ALS and mitochondrial dysfunction", "pmid": "25261932"},
{"claim": "Mitochondrial-derived vesicles are an emerging pathway for mitochondrial quality control", "pmid": "23870199"},
{"claim": "PIKFYVE inhibition preserves mitochondrial function", "pmid": "36754049"}
],
"evidence_against": [
{"claim": "CHCHD10 loss-of-function causes ALS—releasing CHCHD10 from mitochondria would worsen ALS", "pmid": "25261932"},
{"claim": "MDVs fuse with lysosomes for degradation, not with autophagosomes for secretion—no exocytic MDV pathway exists", "pmid": "23870199"},
{"claim": "Preserved mitochondria in PIKFYVE-inhibited cells likely cannot be degraded (blocked mitophagy), not protected", "pmid": "15548221"},
{"claim": "PIKFYVE inhibition impairs lysosomal function, paradoxically blocking MDV quality control", "pmid": "22990836"},
{"claim": "No PI(3,5)P2-regulated kinase demonstrated to phosphorylate CHCHD10", "pmid": "26083769"}
],
"key_gaps": [
"Therapeutic logic is inverted: depleting neuroprotective mitochondrial protein proposed as therapy",
"No exocytic MDV pathway exists in literature",
"'Protected mitochondria' interpretation likely conflates blocked mitophagy with protection"
],
"required_experiments": [
"CHCHD10 subcellular localization during PIKFYVE inhibition",
"Phospho-mimetic vs phospho-dead CHCHD10 knock-in",
"MDV inhibitor (glyburide) blocks therapeutic benefit"
],
"red_flags": ["Inverted therapeutic logic", "Non-existent exocytic MDV pathway", "Misinterpretation of preserved mitochondria"]
}
],
"knowledge_edges": [
{"subject": "PIKFYVE", "predicate": "generates", "object": "PI(3,5)P2", "context": "lipid kinase reaction", "pmid": "15548221"},
{"subject": "PIKFYVE", "predicate": "inhibits", "object": "autophagosome-lysosome fusion", "context": "therapeutic mechanism paradox", "pmid": "22990836"},
{"subject": "PIKFYVE", "predicate": "targeted_by", "object": "Apilimod", "context": "clinical development", "pmid": "26839307"},
{"subject": "PIKFYVE", "predicate": "targeted_by", "object": "YM-201636", "context": "research tool", "pmid": "22990836"},
{"subject": "PIKFYVE", "predicate": "associated_with", "object": "ALS motor neuron protection", "context": "therapeutic potential", "pmid": "36754049"},
{"subject": "TMED10", "predicate": "part_of", "object": "CUPS pathway", "context": "unconventional secretion", "pmid": "31722219"},
{"subject": "TMED10", "predicate": "mutated_in", "object": "Congenital disorders of glycosylation", "context": "disease relevance", "pmid": "29395064"},
{"subject": "TDP-43", "predicate": "substrate_of", "object": "unconventional secretion", "context": "ALS pathology", "pmid": "29395064"},
{"subject": "FUS", "predicate": "substrate_of", "object": "unconventional secretion", "context": "ALS pathology", "pmid": "29395064"},
{"subject": "RAB27A", "predicate": "controls", "object": "lysosomal exocytosis", "context": "specialized secretory cells", "pmid": "15102840"},
{"subject": "RAB27A", "predicate": "dispensable_for", "object": "lysosomal exocytosis in most cells", "context": "cell-type restriction", "pmid": "22573891"},
{"subject": "ALIX", "predicate": "interacts_with", "object": "ESCRT-III/CHMP4B", "context": "endosomal sorting", "pmid": "16903783"},
{"subject": "ALIX", "predicate": "knockdown_associated_with", "object": "tauopathy", "context": "neurodegeneration phenotype", "pmid": "29189420"},
{"subject": "CHCHD10", "predicate": "mutated_in", "object": "ALS", "context": "mitochondrial dysfunction", "pmid": "25261932"},
{"subject": "CHCHD10", "predicate": "regulates", "object": "mitochondrial cristae structure", "context": "via OPA1-like function", "pmid": "25261932"},
{"subject": "CHCHD10", "predicate": "phosphorylated_by", "object": "CK2", "context": "not PI(3,5)P2-regulated", "pmid": "26083769"},
{"subject": "MDV", "predicate": "fuses_with", "object": "lysosomes", "context": "mitochondrial quality control", "pmid": "23870199"},
{"subject": "YKT6", "predicate": "forms_complex_with", "object": "SNAP29-STX17", "context": "canonical ER-Golgi trafficking", "pmid": "29107332"},
{"subject": "YKT6", "predicate": "mediates", "object": "unconventional secretion", "context": "leaderless proteins", "pmid": "29107332"},
{"subject": "STX11", "predicate": "mutated_in", "object": "Hemophagocytic lymphohistiocytosis", "context": "immune disorder", "pmid": "16177804"},
{"subject": "STX11", "predicate": "associated_with", "object": "phagosome maturation", "context": "microglial function", "pmid": "24501467"},
{"subject": "TREM2", "predicate": "variant_risk_factor_for", "object": "ALS/FTD", "context": "microglial phagocytosis", "pmid": "27974619"},
{"subject": "P2RX7", "predicate": "mediates", "object": "microglial phagocytosis", "context": "debris clearance", "pmid": "28753427"},
{"subject": "HSP90B1", "predicate": "chaperone_for", "object": "ER protein folding", "context": "ER stress response", "pmid": "29987195"},
{"subject": "TFG", "predicate": "mutated_in", "object": "Hereditary spastic paraplegia 57", "context": "impaired ER export", "pmid": "23091053"},
{"subject": "ANXA2", "predicate": "forms_complex_with", "object": "S100A10", "context": "membrane-cytoskeleton dynamics", "pmid": "24043799"},
{"subject": "ER stress", "predicate": "activates", "object": "ERAD pathway", "context": "protein quality control", "pmid": "28704975"},
{"subject": "ER-phagy receptors", "predicate": "include", "object": "FAM134B, RTN3, CCPG1", "context": "ER quality control", "pmid": "30104642"},
{"subject": "Secretory autophagy", "predicate": "mediates", "object": "autophagosome-plasma membrane fusion", "context": "unconventional secretion", "pmid": "25468908"},
{"subject